Inactief instrument

Andere talen InDex Pharmaceuticals Holding AB Nasdaq Stockholm

Aandelen

slotkoers Nasdaq Stockholm Andere beurzen
- ^SEK	-

07/05	InDex Pharmaceuticals Holding AB (publ) stemt in met de verkiezing van Karl Tobieson tot lid van de Raad van Bestuur	CI
26/04	InDex Pharmaceuticals Holding AB (publ) rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

InDex Pharmaceuticals has entered into a conditional agreement regarding a reverse merger with Flerie	20/05
Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)	07/05
InDex Pharmaceuticals Holding AB Approves the Election of Karl Tobieson as Board Member	07/05
Notice of extraordinary general meeting in InDex Pharmaceuticals Holding AB (publ)	06/05
InDex Pharmaceuticals provides a status update and informs about Extraordinary General Meeting on June 10, 2024	06/05
InDex Pharmaceuticals Holding AB (publ) interim report January - March 2024	26/04
InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04
InDex Pharmaceuticals brings forward the publication of the interim report for Q1 2024	22/04
InDex Pharmaceuticals provides a company update	08/04
InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2023	08/04
Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)	05/04
Index Pharmaceuticals Holding AB Announces Board Resignations	05/04
InDex Pharmaceuticals CEO, CFO to Step Down as Operations Cease	26/03
CEO and CFO both to leave InDex Pharmaceuticals	26/03
Index Pharmaceuticals Holding AB Announces Resignation of Johan Giléus as Deputy CEO	26/03
InDex Pharmaceuticals Holding AB Announces Resignation of Jenny Sundqvist as CEO, Effective September 26, 2024	26/03
InDex Pharmaceuticals Holding AB Announce Resignation of Johan Giléus as CFO, Effective September 26, 2024	26/03
InDex Pharmaceuticals Launches Strategic Review Amid Decision to Stop Cobitolimod Development	27/02
InDex Pharmaceuticals provides an update on company's future	26/02
InDex Pharmaceuticals discontinues the development of cobitolimod	26/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen InDex Pharmaceuticals Holding AB Nasdaq Stockholm

Aandelen

Andere talen

Filters